NF-κB Transcriptional Activity Is Modulated by FK506-binding Proteins FKBP51 and FKBP52

A ROLE FOR PEPTIDYL-PROLYL ISOMERASE ACTIVITY*

  1. Mario D. Galigniana,1
  1. From the Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires and Instituto de Química Biológica de Ciencias Exactas y Naturales (IQUIBICEN)/Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, C1428ADN Argentina,
  2. §Border Biomedical Research Center and Department of Biological Sciences, University of Texas, El Paso, Texas 79968,
  3. Laboratorio de Arquitectura Nuclear, Instituto de Biología y Medicina Experimental/CONICET, Buenos Aires C1428ADN, Argentina, and
  4. Laboratorio de Receptores Nucleares, Instituto de Biología y Medicina Experimental/CONICET, Buenos Aires C1428ADN, Argentina
  1. 1 To whom correspondence should be addressed: IBYME/CONICET, Vuelta de Obligado 2490, Rm. 304, Buenos Aires C1428ADN, Argentina. Tel.: 54-11-4783-2869 (ext. 304); Fax: 54-11-4786–2564; E-mail: mgaligniana{at}conicet.gov.ar.

Background: Hsp90 binding immunophilins may be regulators of the NF-κB mechanism of action.

Results: FKBP51 and FKBP52 show antagonistic properties on the nuclear accumulation and transcriptional activity of NF-κB.

Conclusion: Both immunophilins modulate NF-κB trafficking and NF-κB transcription when they are recruited to the promoter regions of target genes.

Significance: The competitive effect between both immunophilins in different cell types may explain the pleiotropic actions of NF-κB.

Abstract

Hsp90 binding immunophilins FKBP51 and FKBP52 modulate steroid receptor trafficking and hormone-dependent biological responses. With the purpose to expand this model to other nuclear factors that are also subject to nuclear-cytoplasmic shuttling, we analyzed whether these immunophilins modulate NF-κB signaling. It is demonstrated that FKBP51 impairs both the nuclear translocation rate of NF-κB and its transcriptional activity. The inhibitory action of FKBP51 requires neither the peptidylprolyl-isomerase activity of the immunophilin nor its association with Hsp90. The TPR domain of FKBP51 is essential. On the other hand, FKBP52 favors the nuclear retention time of RelA, its association to a DNA consensus binding sequence, and NF-κB transcriptional activity, the latter effect being strongly dependent on the peptidylprolyl-isomerase activity and also on the TPR domain of FKBP52, but its interaction with Hsp90 is not required. In unstimulated cells, FKBP51 forms endogenous complexes with cytoplasmic RelA. Upon cell stimulation with phorbol ester, the NF-κB soluble complex exchanges FKBP51 for FKBP52, and the NF-κB biological effect is triggered. Importantly, FKBP52 is functionally recruited to the promoter region of NF-κB target genes, whereas FKBP51 is released. Competition assays demonstrated that both immunophilins antagonize one another, and binding assays with purified proteins suggest that the association of RelA and immunophilins could be direct. These observations suggest that the biological action of NF-κB in different cell types could be positively regulated by a high FKBP52/FKBP51 expression ratio by favoring NF-κB nuclear retention, recruitment to the promoter regions of target genes, and transcriptional activity.

Footnotes

  • * This work was supported, in whole or in part, by National Institutes of Health Grants 5 G12 RR008124 (Border Biomedical Research Center from the National Center for Research Resources) and 8 G12 MD007592 (National Institute on Minority Health and Health Disparities (to M. B. C.). This work was also supported by Agencia Nacional de Promoción Científica y Tecnológica de Argentina Grants PICT-2010-1170 and PICT-2011-1715 (to M. D. G.), PICT-2010-2215 (to A. G. E.), and PICT-2012-2612 (to G. P.-P.) and University of Buenos Aires Grants UBACYT-2011/14-GC (to M. D. G.), UBACYT 2011/13-IJ, and UBACYT 2013/15-IF (to A. G. E.).

  • Received May 19, 2014.
  • Revision received July 30, 2014.
Table of Contents

Submit your work to JBC.

You'll be in good company.